Board of Directors
Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on early to late stage investments in biopharmaceuticals. Ron was one of the founders of New Leaf in 2005, and today has over 2 decades of experience investing in and building companies focused on developing novel medicines that address important unmet medical needs. Prior to his start in venture capital in 1998, Ron was a strategy and operations consultant to clients in the pharmaceutical and medical device industries. His experience also includes a number of sales and marketing positions with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (M.B.A.) and Cornell University (B.S.).
Martin Mackay, Ph.D.
Dr. Mackay serves as Chairman of the Board and is a co-founder of Rallybio. He has more than 30 years of experience in drug discovery and development. Most recently, he was Executive Vice President, Global Head of R&D at Alexion Pharmaceuticals, where he oversaw the development of multiple pre-clinical and clinical programs, resulting in new rare disease indications, for Soliris® (eculizumab), as well as the new rare disease therapies Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa). Prior to Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca, where he led all R&D functions on a global basis. Prior to AstraZeneca, he held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D. Dr. Mackay received his Ph.D. in molecular genetics from the University of Edinburgh, Scotland.
Kush M. Parmar, MD Ph.D.
Kush is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Akouos, Arvinas (NASDAQ: ARVN), Audentes (NASDAQ: BOLD), Homology and scPharmaceuticals (NASDAQ: SCPH). He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and was Board Observer for Envoy (acquired by Takeda), Achaogen (NASDAQ: AKAO) and Pulmatrix (NASDAQ: PULM). Dr. Parmar serves on Advisory Boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. He is a Fellow of the Society of Kauffman Fellows.
Previously, he was an NIH-sponsored MD/Ph.D. Physician Scientist Fellow at Harvard Medical School, where he completed clinical clerkships at the Massachusetts General Brigham and Women’s Hospitals. Dr. Parmar received an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an MD from Harvard Medical School.
Timothy Shannon, MD
Dr. Shannon is a Venture Partner at Canaan Partners. He also serves on the boards of Canaan portfolio companies Arvinas (NASDAQ: ARVN), IDEAYA Biosciences, Nextcure, Spyryx Biosciences, Vivace Therapeutics, and VaxInnate Corporation.
Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. Prior to his career in industry, Dr. Shannon was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine.
Dr. Shannon received his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University. He earned his medical degree from the University of Connecticut and has a bachelor’s in Chemistry from Amherst College.